Back to search results

Stellate Ganglion Block for Atrial Fibrillation After CABG Surgery

This study is looking at whether a nerve block can help prevent an irregular heartbeat called atrial fibrillation (AF) after heart bypass surgery. If you are 40 years or older and scheduled for isolated coronary artery bypass grafting (CABG) surgery, you might be able to join. Participants will receive either liposomal bupivacaine, a long-acting pain medication, or a saline placebo (inactive substance) injection near a nerve in the neck (stellate ganglion block) before surgery. Researchers will then check for new cases of atrial fibrillation within one week after your surgery. The study aims to enroll 450 participants, but its current recruitment status is unclear.

Study design
This is an interventional study comparing two treatments in 450 participants. You would receive either liposomal bupivacaine or a saline placebo prior to surgery.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will monitor you for new-onset atrial fibrillation for one week after your surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07570940

A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

Not Yet Recruiting
PHASE4Ages 40+InterventionalTreatment
Mayo Clinic
~450 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:Liposomal bupivacainePlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of new-onset postoperative atrial fibrillation (POAF) within one week of isolated coronary artery bypass grafting (CABG) surgery
Measured over 1 week

Conditions

Coronary Artery Disease
Atrial Fibrillation

Explore related trials

Atrial FibrillationCoronary Artery Disease

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Juan G. Ripoll Sanz, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Anesthesia Clinical Research Unit (ACRU) Study Team
[email protected]
866-265-9263
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged ≥40 years scheduled to undergo isolated coronary artery bypass grafting will be eligible.
Cases will also remain eligible if, after the initial surgical listing, additional procedures-such as valvular interventions or septal myectomy-are performed, OR if coronary artery bypass grafting (CABG) is listed as the primary intervention with other procedures noted as possible additional interventions.
Cases will also remain eligible if additional procedures-such as left atrial appendage ligation, MAZE procedure, cryotherapy, or pulmonary vein isolation-are concomitantly listed with the CABG.

Exclusion

Permanent atrial fibrillation
Mechanical circulatory support implant or explant
Procedures not requiring cardiopulmonary bypass
Heart and/or lung transplant patients
Active infection/sepsis
Pre-operative anti-arrhythmic use (aside from beta-blockers).
Participant has a known allergy to adhesives or hydrogels.
Participant has a visible skin injury or broken skin at the location for study device placement.
Participant does not have the competency to wear the device for the prescribed patching period.
Participant has a neuro-stimulator, as it may disrupt the quality of ECG data.
Participants who are pregnant. In accordance with Mayo Clinic's standard cardiac surgery protocol, all women of childbearing potential undergo routine preoperative pregnancy testing. Pregnancy status will therefore be confirmed prior to enrollment. Any participant with a positive pregnancy test will be deemed ineligible and will not be enrolled in the study.
Participants who lack the capacity to provide informed consent will not be approached or enrolled in this study.

What this trial measures

  • Incidence of new-onset postoperative atrial fibrillation (POAF) within one week of isolated coronary artery bypass grafting (CABG) surgery1 week

    Total number of patients to experience postoperative atrial fibrillation within one week of CABG surgery.